Kanatsuka Azuma, Tokuyama Yoshiharu, Nozaki Osamu, Matsui Kana, Egashira Tohru
Diabetes Centre, Kasori Hospital, Chiba, Japan.
Metabolism. 2002 Sep;51(9):1161-5. doi: 10.1053/meta.2002.34707.
Polymorphisms in beta-cell transcription factor genes, Ala45Thr in the NeuroD1 gene and Arg121Trp in the Pax4 gene, have been reported. To clarify the role of these mutations in the pathogenesis of late-onset diabetes, we examined the insulin secretion and sensitivity in diabetic patients carrying the homozygous mutation in the NeuroD1 gene or Pax4 gene. We screened for the polymorphisms in NeuroD1 and Pax4 genes in 296 late-onset diabetic patients and 177 unrelated control subjects over 60 years of age. Genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) followed by direct sequencing. Acute insulin secretion was evaluated using a 2-compartment model analysis of C-peptide kinetics after intravenous glucose load (CS1). Insulin sensitivity was estimated by the insulin-modified minimal model analysis (Si). Four diabetic patients carried the homozygous mutation (Thr/Thr) in the NeuroD1 gene and 3 patients carried the homozygous mutation (Trp/Trp) in the Pax4 gene, while both homozygous mutations were not detected in the control subjects. In patients A, B, C, and D with homozygous mutations in NeuroD1, CS1 (normal range, 6.8 to 18.5 ng/mL/min) was 0.508, 1.481, 1.223, and 1.584 ng/mL/min, respectively, and Si (normal range, 2.6 to 7.6 x 10(-4)/min/[microU/mL]) was 0.727, 3.31, 3.79, and 0.00 x 10(-4)/min/(microU/mL), respectively. In patients X, Y, and Z with homozygous mutation in Pax4, CS was 0.418, 0.208, and 1.279 ng/mL/min, respectively, and Si was 1.11, 2.88, and 0.00 x 10(-4)/min/(microU/mL), respectively. Since acute insulin secretion in response to glucose was markedly impaired and insulin resistance was varied in the patients carrying the homozygous mutations in the NeuroD1 and Pax4 genes, the mutations are ones of the factors involved in the beta-cell dysfunction and do not relate to the insulin resistance. These homozygous mutations appear to play a part in the pathogenesis of beta-cell defect in about 2.5% of Japanese patients with late-onset diabetes.
已有报道称,β细胞转录因子基因存在多态性,即NeuroD1基因中的Ala45Thr和Pax4基因中的Arg121Trp。为阐明这些突变在晚发型糖尿病发病机制中的作用,我们检测了携带NeuroD1基因或Pax4基因纯合突变的糖尿病患者的胰岛素分泌及敏感性。我们在296例60岁以上的晚发型糖尿病患者和177名无关对照受试者中筛查了NeuroD1和Pax4基因的多态性。通过聚合酶链反应-限制性片段长度多态性(PCR-RFLP),随后进行直接测序来进行基因分型。静脉注射葡萄糖负荷后,使用C肽动力学的两室模型分析(CS1)评估急性胰岛素分泌。通过胰岛素改良最小模型分析(Si)估计胰岛素敏感性。4例糖尿病患者携带NeuroD1基因的纯合突变(Thr/Thr),3例患者携带Pax4基因的纯合突变(Trp/Trp),而对照受试者中未检测到这两种纯合突变。在携带NeuroD1纯合突变的患者A、B、C和D中,CS1(正常范围为6.8至18.5 ng/mL/min)分别为0.508、1.481、1.223和1.584 ng/mL/min,Si(正常范围为2.6至7.6×10⁻⁴/min/[μU/mL])分别为0.727、3.31、3.79和0.00×10⁻⁴/min/(μU/mL)。在携带Pax4纯合突变的患者X、Y和Z中,CS分别为0.418、0.208和1.279 ng/mL/min,Si分别为1.11、2.88和0.00×10⁻⁴/min/(μU/mL)。由于携带NeuroD1和Pax4基因纯合突变的患者对葡萄糖的急性胰岛素分泌明显受损且胰岛素抵抗各不相同,这些突变是参与β细胞功能障碍的因素之一,与胰岛素抵抗无关。这些纯合突变似乎在约2.5%的日本晚发型糖尿病患者的β细胞缺陷发病机制中起作用。